Thursday, November 17, 2022 9:09:04 PM
Adaptive trial by virtue of the fact that GBM is an orphan disease with the Statistical Analysis Plan and it's endpoints being pre-specified and submitted to regulators before unblinding, the fact is that the peer-reviewed journal concluded ( reviewed by over 70 top neuro surgeons and cancer specialists ), "
Results were clinically meaningful and statistically significant with an extension of overall survival in both nGBM and rGBM. "Treatment with DCVax-L also had an excellent safety profile and noteworthy tails of long-term survival curves". They don't have to like it but they do have to accept that these groundbreaking results will lead to approvals
Results were clinically meaningful and statistically significant with an extension of overall survival in both nGBM and rGBM. "Treatment with DCVax-L also had an excellent safety profile and noteworthy tails of long-term survival curves". They don't have to like it but they do have to accept that these groundbreaking results will lead to approvals
